PHASE II TRIAL OF ERLOTINIB AS FIRST-LINE THERAPY IN NON-SMALL CELL LUNG CANCER OVER-EXPRESSING EGFR

PHASE II TRIAL OF ERLOTINIB AS FIRST-LINE THERAPY IN NON-SMALL CELL LUNG CANCER OVER-EXPRESSING EGFR

Detalles Bibliográficos
Autores principales: Murphy, F, Church, D, Medley, L, Davies, J, Breen, D, Clelland, C, Mackintosh, D, Mugalaasi, H, Butler, R, Talbot, D
Formato: Journal article
Publicado: 2011
Descripción
Sumario:

Ejemplares similares